Pharmaceutical News
New Drug Access Requires Stable Funding; Medical Experts and Patient Advocates Call for Pricing and Reimbursement Reforms
2026/11/16

The government plans to inject NT$60 billion into the National Health Insurance (NHI) Fund through the 2027 central government budget. Dedicated allocations for provisional payments for new cancer drugs totaled NT$5 billion in each of 2025 and 2026. By the first quarter of 2026, cumulative claims had reached NT$2.132 billion, with more than 2,500 patients benefiting from the program.

Brenda Yen, deputy chief executive officer of the Hope Foundation for Cancer Care, said patients with certain cancers still face coverage restrictions and high out-of-pocket costs. She called for greater transparency in the review process, a clear transition from provisional payment to regular NHI coverage, and assessments that incorporate patients’ quality of life, ability to work, and caregiving burdens.

Hung Tzu-jen, administrative deputy superintendent at Shin Kong Wu Ho-Su Memorial Hospital, advocated for stronger price confidentiality and risk-sharing mechanisms to mitigate the risk of low prices hindering the introduction of new drugs. He also recommended setting price floors for basic medicines and reassessing existing medical services to redirect resources toward clinically valuable new drugs and medical technologies. He called for a clearly defined government funding ratio to maintain reasonable growth in the NHI global budget.

Nicole Huang, a professor at National Yang Ming Chiao Tung University, said health technology assessment (HTA) faces insufficient staffing and resources. Even when comprehensive evidence is available, an inflexible NHI global budget can hinder price negotiations. She called for greater investment in health to prevent treatment disparities arising from disease type or financial circumstances.

【2026-11-11/Liberty Times】